Price (90d)
$36.34Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.26M | $-299.77M | $-0.43 |
| 2024 | $29.05M | $-171.98M | $-0.24 |
| 2023 | $32.71M | $4.35B | $5.55 |
| 2022 | $31.53M | $-1.01B | $-1.42 |
| 2021 | $55.29M | $-845.26M | $-1.26 |
Social Signal Score
Earnings
Mon, Nov 9(in 3 months)
Consensus estimate $-0.35 per share
Typical surprise +3.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.33 vs $-0.30miss
- Wed, May 20$-0.28 vs $-0.29beat
- Fri, Feb 6$-0.24 vs $-0.30beat
- Mon, Nov 10$-0.20 vs $-0.32beat
- Mon, Aug 11$-0.25 vs $-0.25miss
- Thu, May 29$-0.29 vs $-0.26miss
Estimates and results for ROIV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ROIVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsseekingalpha.com·7d ago·Positive
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential
View source ↗